{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:03:31Z","timestamp":1790183011153,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81502123"],"award-info":[{"award-number":["81502123"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973332"],"award-info":[{"award-number":["81973332"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009558","name":"University Natural Science Research Project of Anhui Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009558","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.biopha.2021.111754","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T20:18:04Z","timestamp":1621887484000},"page":"111754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["The pathogenesis, models and therapeutic advances of primary biliary cholangitis"],"prefix":"10.1016","volume":"140","author":[{"given":"Hao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/hep.22042","article-title":"The causes of primary biliary cirrhosis: convenient and inconvenient truths","volume":"47","author":"Gershwin","year":"2008","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.biopha.2021.111754_bib2","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"9777","key":"10.1016\/j.biopha.2021.111754_bib3","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","article-title":"Primary biliary cirrhosis","volume":"377","author":"Selmi","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.biopha.2021.111754_bib4","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1111\/liv.12434","article-title":"Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study","volume":"34","author":"Boonstra","year":"2014","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.biopha.2021.111754_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hep.28859","article-title":"Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis","volume":"65","author":"Dahlqvist","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2021.111754_bib6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.biopha.2021.111754_bib7","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2017.12.033","article-title":"Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment","volume":"16","author":"Lu","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2021.111754_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathol-020712-164014","article-title":"The immunobiology and pathophysiology of primary biliary cirrhosis","volume":"8","author":"Hirschfield","year":"2013","journal-title":"Annu. Rev. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111754_bib9","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2021.111754_bib10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2021.111754_bib11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0168-8278(01)00092-7","article-title":"Ursodeoxycholic acid \u2018mechanisms of action and clinical use in hepatobiliary disorders\u2019","volume":"35","author":"Lazaridis","year":"2001","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2021.111754_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MOG.0000000000000525","article-title":"Obeticholic acid in primary biliary cholangitis: where we stand","volume":"35","author":"Manne","year":"2019","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"10003","key":"10.1016\/j.biopha.2021.111754_bib13","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2021.111754_bib14","unstructured":"US Food and Drug Administration. FDA adds Boxed Warning to highlight correct dosing of ocaliva (obeticholic acid) for patients with a rare chronic liver disease. \u3008https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-highlight-correct-dosing-ocaliva-obeticholic-acid-patients-rare-chronic-liver\u3009 (accessed 14 March 2021)."},{"issue":"3","key":"10.1016\/j.biopha.2021.111754_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/MOG.0b013e3280b079fb","article-title":"Cholangiocyte biology","volume":"23","author":"Bogert","year":"2007","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.biopha.2021.111754_bib16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-1-60761-720-4_14","article-title":"Animal models of primary biliary cirrhosis: materials and methods","volume":"900","author":"Leung","year":"2012","journal-title":"Methods Mol. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2021.111754_bib17","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/hep.1840180315","article-title":"Distribution of B lymphocytes in nonsuppurative cholangitis in primary biliary cirrhosis","volume":"18","author":"Nakanuma","year":"1993","journal-title":"Hepatology"},{"issue":"Pt 11","key":"10.1016\/j.biopha.2021.111754_bib18","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1242\/jeb.029454","article-title":"Molecular physiology and genetics of Na+-independent SLC4 anion exchangers","volume":"212","author":"Alper","year":"2009","journal-title":"J. Exp. Biol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111754_bib19","doi-asserted-by":"crossref","first-page":"C1305","DOI":"10.1152\/ajpcell.00584.2004","article-title":"Cloning and characterization of the human soluble adenylyl cyclase","volume":"288","author":"Geng","year":"2005","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"10","key":"10.1016\/j.biopha.2021.111754_bib20","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1073\/pnas.1322778111","article-title":"Crystal structures of human soluble adenylyl cyclase reveal mechanisms of catalysis and of its activation through bicarbonate","volume":"111","author":"Kleinboelting","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8594","key":"10.1016\/j.biopha.2021.111754_bib21","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0140-6736(88)91894-6","article-title":"Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens","volume":"1","author":"Yeaman","year":"1988","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.28550","article-title":"Soluble adenylyl cyclase regulates bile salt-induced apoptosis in human cholangiocytes","volume":"64","author":"Chang","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.biopha.2021.111754_bib23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep.23783","article-title":"Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis","volume":"52","author":"Lleo","year":"2010","journal-title":"Hepatology"},{"issue":"31","key":"10.1016\/j.biopha.2021.111754_bib24","doi-asserted-by":"crossref","first-page":"10895","DOI":"10.1073\/pnas.0802702105","article-title":"Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease","volume":"105","author":"Takeda","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1055\/s-2007-979469","article-title":"Interpreting serological tests in diagnosing autoimmune liver diseases","volume":"27","author":"Invernizzi","year":"2007","journal-title":"Semin. Liver Dis."},{"issue":"1","key":"10.1016\/j.biopha.2021.111754_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/156652409787314525","article-title":"Innate immunity and primary biliary cirrhosis","volume":"9","author":"Selmi","year":"2009","journal-title":"Curr. Mol. Med."},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/jcp.2004.023507","article-title":"Interferon gamma accelerates NF-kappaB activation of biliary epithelial cells induced by Toll-like receptor and ligand interaction","volume":"59","author":"Harada","year":"2006","journal-title":"J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.23318","article-title":"CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis","volume":"51","author":"Shimoda","year":"2010","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.biopha.2021.111754_bib29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1478-3231.2011.02457.x","article-title":"The role of the innate immune recognition system in the pathogenesis of primary biliary cirrhosis: a conceptual view","volume":"31","author":"Berg","year":"2011","journal-title":"Liver Int."},{"issue":"6","key":"10.1016\/j.biopha.2021.111754_bib30","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1002\/hep.28122","article-title":"Natural killer cells regulate T cell immune responses in primary biliary cirrhosis","volume":"62","author":"Shimoda","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2021.111754_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1084\/jem.20010956","article-title":"Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells","volume":"195","author":"Kita","year":"2002","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaut.2008.05.003","article-title":"CD4 T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary biliary cirrhosis","volume":"31","author":"Shimoda","year":"2008","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.biopha.2021.111754_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaut.2016.12.012","article-title":"Chemokine receptor CXCR3 deficiency exacerbates murine autoimmune cholangitis by promoting pathogenic CD8(+) T cell activation","volume":"78","author":"Ma","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.biopha.2021.111754_bib34","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3389\/fimmu.2020.01619","article-title":"Imbalance of the CD226\/TIGIT immune checkpoint is involved in the pathogenesis of primary biliary cholangitis","volume":"11","author":"Deng","year":"2020","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2021.111754_bib35","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI0214698","article-title":"Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis","volume":"109","author":"Kita","year":"2002","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2249.2009.03898.x","article-title":"Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population","volume":"156","author":"Rong","year":"2009","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2021.111754_bib37","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.21123","article-title":"Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis","volume":"43","author":"Lan","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2021.111754_bib38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0065-2776(08)60490-3","article-title":"The murine autoimmune diabetes model: NOD and related strains","volume":"51","author":"Kikutani","year":"1992","journal-title":"Adv. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111754_bib39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.autrev.2005.02.002","article-title":"NOD mice and autoimmunity","volume":"4","author":"Aoki","year":"2005","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2021.111754_bib40","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1084\/jem.20051911","article-title":"NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis","volume":"203","author":"Irie","year":"2006","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1074-7613(00)80170-3","article-title":"Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease[J]","volume":"12","author":"Gorelik","year":"2000","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.biopha.2021.111754_bib42","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.4049\/jimmunol.177.3.1655","article-title":"Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice","volume":"177","author":"Oertelt","year":"2006","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111754_bib43","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/hep.22226","article-title":"Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice","volume":"47","author":"Yang","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2021.111754_bib44","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaut.2006.04.005","article-title":"IL-2 receptor alpha deficiency and features of primary biliary cirrhosis","volume":"27","author":"Aoki","year":"2006","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.biopha.2021.111754_bib45","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/1074-7613(95)90180-9","article-title":"Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment","volume":"3","author":"Willerford","year":"1995","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.biopha.2021.111754_bib46","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/hep.21385","article-title":"IL-2 receptor alpha(-\/-) mice and the development of primary biliary cirrhosis","volume":"44","author":"Wakabayashi","year":"2006","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.biopha.2021.111754_bib47","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nri2889","article-title":"Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases","volume":"10","author":"Buckner","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib48","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/hep.22651","article-title":"Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis","volume":"49","author":"Zhang","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biopha.2021.111754_bib49","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1053\/j.gastro.2008.02.020","article-title":"Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis","volume":"134","author":"Salas","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.biopha.2021.111754_bib50","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2353\/ajpath.2006.051096","article-title":"Inefficient chronic activation of parietal cells in Ae2a,b(-\/-) mice","volume":"169","author":"Recalde","year":"2006","journal-title":"Am. J. Pathol."},{"issue":"10","key":"10.1016\/j.biopha.2021.111754_bib51","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1096\/fj.08-122598","article-title":"Ae2(a,b)-deficient mice exhibit osteopetrosis of long bones but not of calvaria","volume":"23","author":"Jansen","year":"2009","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib52","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.matbio.2007.09.006","article-title":"The anion exchanger Ae2 is required for enamel maturation in mouse teeth","volume":"27","author":"Lyaruu","year":"2008","journal-title":"Matrix Biol."},{"key":"10.1016\/j.biopha.2021.111754_bib53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaut.2014.02.003","article-title":"IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice","volume":"53","author":"Hodge","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.biopha.2021.111754_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102436","article-title":"Multi-omics: Differential expression of IFN-\u03b3 results in distinctive mechanistic features linking chronic inflammation, gut dysbiosis, and autoimmune diseases","volume":"111","author":"Bae","year":"2020","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.biopha.2021.111754_bib55","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/hep.28641","article-title":"Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance","volume":"64","author":"Bae","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biopha.2021.111754_bib56","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.4049\/jimmunol.167.5.2956","article-title":"Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis","volume":"167","author":"Long","year":"2001","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2021.111754_bib57","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.4049\/jimmunol.170.10.5326","article-title":"Immunization with a xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies","volume":"170","author":"Leung","year":"2003","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib58","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/hep.22390","article-title":"Loss of tolerance in C57BL\/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease","volume":"48","author":"Wakabayashi","year":"2008","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.biopha.2021.111754_bib59","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/hep.24113","article-title":"Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis","volume":"53","author":"Wu","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.biopha.2021.111754_bib60","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1478-3231.2005.01043.x","article-title":"Early development of primary biliary cirrhosis in female C57BL\/6 mice because of poly I:C administration","volume":"25","author":"Okada","year":"2005","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.biopha.2021.111754_bib61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10238-010-0105-6","article-title":"Effect of allogeneic bone marrow-derived mesenchymal stem cells transplantation in a polyI:C-induced primary biliary cirrhosis mouse model","volume":"11","author":"Wang","year":"2011","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.111754_bib62","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2249.2011.04453.x","article-title":"The multi-hit hypothesis of primary biliary cirrhosis: polyinosinic-polycytidylic acid (poly I:C) and murine autoimmune cholangitis","volume":"166","author":"Ambrosini","year":"2011","journal-title":"Clin. Exp. Immunol."},{"issue":"Pt 4","key":"10.1016\/j.biopha.2021.111754_bib63","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1099\/00207713-51-4-1405","article-title":"Proposal of the genus Sphingomonas sensu stricto and three new genera, Sphingobium, Novosphingobium and Sphingopyxis, on the basis of phylogenetic and chemotaxonomic analyses","volume":"51","author":"Takeuchi","year":"2001","journal-title":"Int. J. Syst. Evol. Microbiol"},{"issue":"1","key":"10.1016\/j.biopha.2021.111754_bib64","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1073\/pnas.0608255104","article-title":"Urban aerosols harbor diverse and dynamic bacterial populations","volume":"104","author":"Brodie","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4\u20135","key":"10.1016\/j.biopha.2021.111754_bib65","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/sj.jim.2900732","article-title":"Sphingomonads from marine environments","volume":"23","author":"Cavicchioli","year":"1999","journal-title":"J. Ind. Microbiol. Biotechnol."},{"issue":"11","key":"10.1016\/j.biopha.2021.111754_bib66","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2004.41121.x","article-title":"Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis","volume":"99","author":"Kaplan","year":"2004","journal-title":"Am. J. Gastroenterol."},{"issue":"7032","key":"10.1016\/j.biopha.2021.111754_bib67","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/nature03407","article-title":"Recognition of bacterial glycosphingolipids by natural killer T cells","volume":"434","author":"Kinjo","year":"2005","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2021.111754_bib68","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1046\/j.1432-1327.2000.01189.x","article-title":"Structural analysis of two glycosphingolipids from the lipopolysaccharide-lacking bacterium Sphingomonas capsulata","volume":"267","author":"Kawahara","year":"2000","journal-title":"Eur. J. Biochem."},{"issue":"3","key":"10.1016\/j.biopha.2021.111754_bib69","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited","volume":"36","author":"Paumgartner","year":"2002","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.biopha.2021.111754_bib70","doi-asserted-by":"crossref","first-page":"8882","DOI":"10.3390\/ijms13078882","article-title":"Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode","volume":"13","author":"Kotb","year":"2012","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2021.111754_bib71","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cld.2018.03.007","article-title":"Natural history of primary biliary cholangitis in the ursodeoxycholic acid era: role of scoring systems","volume":"22","author":"Goel","year":"2018","journal-title":"Clin. Liver Dis."},{"issue":"1","key":"10.1016\/j.biopha.2021.111754_bib72","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Gm","year":"2017","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.biopha.2021.111754_bib73","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2018.12.028","article-title":"Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis","volume":"17","author":"Cheung","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.biopha.2021.111754_bib74","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.biopha.2021.111754_bib75","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1111\/j.1572-0241.2001.05270.x","article-title":"Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?","volume":"96","author":"Angulo","year":"2001","journal-title":"Am. J. Gastroenterol."},{"issue":"17","key":"10.1016\/j.biopha.2021.111754_bib76","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2021.111754_bib77","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MOG.0000000000000525","article-title":"Obeticholic acid in primary biliary cholangitis: where we stand","volume":"35","author":"Manne","year":"2019","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"3","key":"10.1016\/j.biopha.2021.111754_bib78","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000371670","article-title":"Bile acids as hormones: the FXR-FGF15\/19 pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Dig. Dis."},{"issue":"10\u2013a\u2013s Suppl","key":"10.1016\/j.biopha.2021.111754_bib79","first-page":"S3","article-title":"Primary biliary cholangitis: medical and specialty pharmacy management update","volume":"22","author":"Bowlus","year":"2016","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2021.111754_bib80","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2021.111754_bib81","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.28932","article-title":"Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis","volume":"65","author":"Samur","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biopha.2021.111754_bib82","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib83","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","article-title":"A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA","volume":"74","author":"Hirschfield","year":"2021","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib84","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.addr.2004.08.009","article-title":"Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide","volume":"57","author":"Fedorak","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.biopha.2021.111754_bib85","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.autrev.2016.07.003","article-title":"Novel therapeutics for primary biliary cholangitis: toward a disease-stage-based approach","volume":"15","author":"Mousa","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib86","first-page":"695","article-title":"Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells","volume":"118","author":"Arenas","year":"2008","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib87","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.24748","article-title":"Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"55","author":"Tsuda","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.biopha.2021.111754_bib88","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ajg.2013.51","article-title":"B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid","volume":"108","author":"Myers","year":"2013","journal-title":"Am. J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.biopha.2021.111754_bib89","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.3748\/wjg.v20.i10.2606","article-title":"Autoantibodies in primary biliary cirrhosis: recent progress in research on the pathogenetic and clinical significance","volume":"20","author":"Yamagiwa","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.biopha.2021.111754_bib90","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/hep.30099","article-title":"Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis: a phase 2 randomized controlled trial","volume":"70","author":"Khanna","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2021.111754_bib91","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.3389\/fimmu.2018.02534","article-title":"Anti-drug antibodies against a novel humanized anti-CD20 antibody impair its therapeutic effect on primary biliary cholangitis in human CD20- and Fc\u03b3R-expressing mice","volume":"9","author":"Moritoki","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib92","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"issue":"23","key":"10.1016\/j.biopha.2021.111754_bib93","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2021.111754_bib94","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/hep.30552","article-title":"Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis","volume":"70","author":"Honda","year":"2019","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.biopha.2021.111754_bib95","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","article-title":"Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score","volume":"61","author":"Hegade","year":"2016","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib96","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2021.111754_bib97","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1002\/hep.25919","article-title":"Liver X receptor beta and peroxisome proliferator-activated receptor delta regulate cholesterol transport in murine cholangiocytes","volume":"56","author":"Xia","year":"2012","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.biopha.2021.111754_bib98","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.3390\/ijms19082189","article-title":"The opportunities and challenges of peroxisome proliferator-activated receptors ligands in clinical drug discovery and development","volume":"19","author":"Hong","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2021.111754_bib99","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2021.111754_bib100","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2021.111754_bib101","unstructured":"Genfit. Elafibranor in PBC. \u3008https:\/\/www.genfit.com\/pipeline\/elafibranor-in-pbc\/\u3009 (accessed 24 March 2021)."},{"issue":"6","key":"10.1016\/j.biopha.2021.111754_bib102","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/hep.20705","article-title":"Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis","volume":"41","author":"Harada","year":"2005","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.biopha.2021.111754_bib103","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPARalpha\/gamma agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models","volume":"38","author":"Jain","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2021.111754_bib104","doi-asserted-by":"crossref","unstructured":"Schramm C., Hirschfield G., Mason AL, et al. Early assessment of safety and efficacy of tropifexor, a potent non-bile acid FXR agonist, in patients with primary biliary cholangitis: an interim analysis of an ongoing phase 2 study. European Association for the Study of the Liver International Liver Congress; Paris, France; April 11\u201315, 2018.","DOI":"10.1016\/S0168-8278(18)30426-4"},{"issue":"3","key":"10.1016\/j.biopha.2021.111754_bib105","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.biopha.2021.111754_bib106","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/hep4.1193","article-title":"Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist","volume":"2","author":"Erstad","year":"2018","journal-title":"Hepatol. Commun."},{"issue":"3","key":"10.1016\/j.biopha.2021.111754_bib107","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000450905","article-title":"Fibroblast growth factor 15\/19 in hepatocarcinogenesis","volume":"35","author":"Alvarez-Sola","year":"2017","journal-title":"Dig. Dis."},{"issue":"12","key":"10.1016\/j.biopha.2021.111754_bib108","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","article-title":"Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19","volume":"74","author":"Zhou","year":"2014","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.biopha.2021.111754_bib109","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib110","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s10620-013-2920-6","article-title":"Chemokine-chemokine receptor CCL2-CCR2 and CX3CL1-CX3CR1 axis may play a role in the aggravated inflammation in primary biliary cirrhosis","volume":"59","author":"Sasaki","year":"2014","journal-title":"Dig. Dis. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2021.111754_bib111","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s10620-013-2734-6","article-title":"Clinicopathological significance of serum fractalkine in primary biliary cirrhosis","volume":"58","author":"Harada","year":"2013","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2021.111754_bib112","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/hep.24681","article-title":"Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes","volume":"55","author":"Studer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2021.111754_bib113","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.3389\/fimmu.2018.02534","article-title":"Anti-drug antibodies against a novel humanized anti-CD20 antibody impair its therapeutic effect on primary biliary cholangitis in human CD20- and Fc\u03b3R-expressing mice","volume":"9","author":"Moritoki","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2021.111754_bib114","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1124\/jpet.118.254268","article-title":"The selective sphingosine 1-phosphate receptor modulator etrasimod regulates lymphocyte trafficking and alleviates experimental colitis","volume":"369","author":"Al-Shamma","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2021.111754_bib115","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3389\/fonc.2018.00357","article-title":"Transforming growth factor-\u03b2-induced cell plasticity in liver fibrosis and hepatocarcinogenesis","volume":"8","author":"Fabregat","year":"2018","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib116","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.freeradbiomed.2012.05.007","article-title":"Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4\/NOX1 inhibitor in vivo","volume":"53","author":"Jiang","year":"2012","journal-title":"Free Radic. Biol. Med."},{"issue":"1 Pt A","key":"10.1016\/j.biopha.2021.111754_bib117","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/j.bbagen.2016.09.009","article-title":"Pharmacological inhibition of NOX4 ameliorates alcohol-induced liver injury in mice through improving oxidative stress and mitochondrial function","volume":"1861","author":"Sun","year":"2017","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"1","key":"10.1016\/j.biopha.2021.111754_bib118","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/S0618-8278(19)30002-7","article-title":"GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: interim efficacy results of a phase 2 clinical trial","volume":"70","author":"Dalekos","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2021.111754_bib119","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2018.09.010","article-title":"Gut microbiota translocation promotes autoimmune cholangitis","volume":"95","author":"Ma","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.biopha.2021.111754_bib120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mam.2017.06.002","article-title":"Interactions between gut bacteria and bile in health and disease","volume":"56","author":"Long","year":"2017","journal-title":"Mol. Asp. Med."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2021.111754_bib121","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jgh.12029","article-title":"Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis","volume":"28","author":"Wang","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"20","key":"10.1016\/j.biopha.2021.111754_bib122","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1089\/scd.2013.0500","article-title":"Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis","volume":"23","author":"Wang","year":"2014","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.biopha.2021.111754_bib123","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.2147\/DDDT.S170518","article-title":"Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis","volume":"12","author":"Hu","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.biopha.2021.111754_bib124","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fphar.2018.00931","article-title":"Ileal bile acid transporter inhibition for the treatment of chronic constipation, cholestatic pruritus, and NASH","volume":"9","author":"Al-Dury","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111754_bib125","first-page":"189","article-title":"Advances in studies of ileal apical sodium-dependent bile acid transporter","volume":"52","author":"Ge","year":"2017","journal-title":"Acta Pharm. Sin. B"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221005369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221005369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:05:28Z","timestamp":1774530328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221005369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":125,"alternative-id":["S0753332221005369"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111754","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pathogenesis, models and therapeutic advances of primary biliary cholangitis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111754"}}